Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence

Author:

Liu Kevin X.1ORCID,Shin Kee‐Young2ORCID,Thakuria Manisha34ORCID,Schoenfeld Jonathan D.13ORCID,Tishler Roy B.13ORCID,Silk Ann W.35ORCID,Yoon Charles H.36ORCID,Fite Elliott1ORCID,Margalit Danielle N.13ORCID

Affiliation:

1. Department of Radiation Oncology Brigham & Women's Hospital/Dana‐Farber Cancer Institute Boston Massachusetts USA

2. Department of Data Science Dana‐Farber Cancer Institute Boston Massachusetts USA

3. Merkel Cell Carcinoma Center of Excellence Dana‐Farber/Brigham & Women’s Cancer Center Boston Massachusetts USA

4. Department of Dermatology Brigham & Women’s Hospital Boston Massachusetts USA

5. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

6. Division of Surgical Oncology Department of Surgery Dana‐Farber/Brigham and Women's Cancer Center Boston Massachusetts USA

Abstract

ABSTRACTBackgroundSerum antibodies to the Merkel oncoprotein (AMERK) are detectable in approximately 50% of patients with Merkel cell carcinoma (MCC) and can be used to monitor for recurrence. The objective of this study was to characterize AMERK levels in patients receiving curative‐intent radiation therapy (RT) for MCC and identify associations between AMERK and recurrence.MethodsThis was a retrospective study of patients with MCC who had baseline AMERK measurements before they received curative‐intent RT from 2010 to 2020. Event‐free survival (EFS) was calculated using the Kaplan–Meier method and Cox regression. The cumulative incidence of MCC‐related recurrence (CIMR) was analyzed with death as a competing risk and the Gray test.ResultsThe authors identified 88 patients who had baseline AMERK measurements, including 52 (59%) with detectable levels. AMERK positivity was associated with younger median age (67.8 vs. 72.0 years; p = .02) and tumor site (p = 0.02), with lower rates for those who had disease in the head/neck region (17.3% vs. 44.4%). EFS (71.3% vs. 60.4%; p = .30) and CIMR (24.4% vs. 39.6%; p = .23) were more favorable in AMERK‐positive patients. Two patients had recurrences in the RT field, and both were AMERK‐negative at baseline. The median time to AMERK nadir after RT was 11.2 months; and, in a 6‐month post‐RT landmark analysis, the proportion of patients who were AMERK‐positive who became negative or who had levels that decreased by ≥50% were not associated with EFS (87.1% vs. 85.0%; p = .90) or CIMR (12.9% vs. 15.0%; p = .62).ConclusionsPositive AMERK baseline levels were correlated with younger age at MCC diagnosis and nonhead and neck tumor location, possibly related to the distribution of viral etiology. A specific post‐RT AMERK decline correlating with EFS could not be identified.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3